Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

Nuwellis publishes strong pediatric Aquadex data; 87% survival, FDA label expansion pending.

What the company is saying

Nuwellis, Inc. (NASDAQ:NUWE) is highlighting the publication of a multicenter study in Pediatric Nephrology evaluating its Aquadex SmartFlow System in 91 pediatric patients, including infants under 10 kg. The company frames the results as 'important clinical evidence' supporting Aquadex use in critically ill pediatric populations, emphasizing high survival (87%) and procedure completion (86.5%) rates. The announcement stresses that Nuwellis funded the study but did not influence data analysis or publication, aiming to bolster credibility. Michelle Starr, M.D., and Stuart Goldstein, M.D. (Director of Clinical Strategy at Nuwellis, appointed March 2026), are named as lead authors and spokespeople, underlining institutional clinical expertise. The company also notes it has completed a pre-submission meeting with the FDA to expand Aquadex’s cleared labeling from patients weighing 20 kg and above to those weighing 5 kg and above. The tone is confident, with emphasis on real-world, multicenter evidence and the potential to address an unmet clinical need in very small children.

What the data suggests

The ULTRA-Peds Registry study evaluated 91 pediatric patients treated with Aquadex across seven children's hospitals, with 62% weighing less than 10 kg and 41 patients under 5 kg. Survival through the treatment course was 87%, and 86.5% of procedures were completed without interruption, indicating a high level of device reliability and clinical feasibility. Approximately 68% of cases with complete data lasted their planned treatment duration, with most early terminations due to vascular access or clotting—common challenges in this population. The study expands the evidence base to a total of 208 pediatric patients when combined with prior research. The current FDA-cleared indication for Aquadex is for patients 20 kg and above, but the company is seeking to lower this to 5 kg, which would broaden the addressable market. No financial metrics or commercial adoption rates are disclosed, so the immediate revenue or profit impact cannot be assessed. The clinical data is robust and specific, but comparative efficacy, statistical significance, and commercial implications are not addressed.

Analysis

The announcement is primarily a factual disclosure of clinical study results, with detailed numerical data on patient outcomes and device performance. Nearly all claims are realised and supported by specific figures (e.g., 87% survival, 86.5% procedures completed without interruption), and the only forward-looking statement is the pursuit of expanded FDA labeling, which is described as a regulatory process rather than a guaranteed outcome. There is no evidence of exaggerated language or narrative inflation; the tone is positive but proportionate to the disclosed results. No large capital outlay or immediate financial impact is mentioned, and the benefits of potential label expansion are not quantified or time-bound. The absence of financial metrics (revenue, profit, cash flow) means the signal cannot be strong_positive, but the clinical evidence is robust and well-presented.

Risk flags

• ●Regulatory risk remains significant, as the expanded FDA labeling for Aquadex use in patients weighing 5 kg and above is not yet approved. Without this, commercial uptake in the smallest pediatric segment may be limited.
• ●Operational risk is present due to the technical challenges of treating very small infants, as evidenced by early circuit terminations from vascular access or clotting issues. These complications could affect real-world adoption and outcomes.
• ●Disclosure risk exists because the announcement does not provide financial data, adoption rates, or comparative efficacy, making it difficult to assess the commercial impact or competitive positioning of Aquadex in the pediatric market.

Bottom line

Nuwellis has published detailed multicenter data showing 87% survival and 86.5% uninterrupted procedure rates for Aquadex in critically ill pediatric patients, including infants under 10 kg. The study, which increases the evidence base to 208 pediatric patients, supports the feasibility of Aquadex in this challenging population but does not address comparative efficacy or commercial outcomes. The company is seeking FDA label expansion to include patients as small as 5 kg, but no decision or timeline is provided, so any market impact is not immediate. Operational challenges, such as vascular access and clotting, remain barriers to broader adoption. Investors should recognize the clinical credibility of these results but will need to wait for regulatory progress and financial disclosures to gauge commercial upside. The most important takeaway is that Nuwellis is building a strong clinical case for Aquadex in small children, but regulatory and commercial milestones are still pending.

Announcement summary

(NASDAQ:NUWE) Nuwellis, Inc. announced the publication of results from a multicenter study titled "Kidney Support in Infants and Children using Aquadex: Findings from the ULTRA-Peds Registry" in Pediatric Nephrology. The study provides clinical evidence supporting the use of the Aquadex SmartFlow System ultrafiltration technology in pediatric patients, including infants and children weighing less than 10 kg. The publication was authored by Michelle C. Starr, M.D., MPH; Stuart L. Goldstein, M.D.; Shina Menon, M.D.; David Askenazi, M.D., MSPH; David M. Kwiatkowski, M.D.; and Alexandru R. Constantinescu, M.D. The ULTRA-Peds study was funded by Nuwellis, Inc. via a grant to the Acute Kidney Injury Critical Care Research Foundation, managed by Watermark Partners. Nuwellis had no input on data analysis, presentation, or publication of the results. The study evaluated 91 pediatric patients treated with Aquadex across seven children's hospitals, examining patient outcomes, treatment characteristics, and device performance. Of the enrolled patients, 62% weighed less than 10 kg, including 41 patients weighing less than 5 kg. Results showed that 87% of patients survived their Aquadex treatment course, and 86.5% of procedures were completed without interruption. Approximately 68% of cases with complete data lasted their planned treatment duration. Most circuits that ended early did so because of vascular access problems or clotting. Stuart Goldstein, M.D., Director of Clinical Strategy at Nuwellis and co-author of the study, stated that the ULTRA-Peds Registry provides important multicenter data on both clinical outcomes and device performance, demonstrating the feasibility of Aquadex therapy in critically ill pediatric patients, including very small infants. Dr. Goldstein’s appointment as Director of Clinical Strategy was first announced in March of this year. The registry first opened in March of 2021. The study builds on previously published research involving Aquadex therapy in children. By combining findings from the ULTRA-Peds Registry with earlier studies, researchers evaluated clinical outcomes across a total of 208 pediatric patients. Earlier this year, Nuwellis announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) seeking to expand Aquadex’s FDA-cleared labeling from patients weighing 20 kg and above to those weighing 5 kg and above. The Aquadex SmartFlow System is currently indicated for continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in hospitalized patients) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider within a clinical setting under physician prescription, both of whom have received training in extracorporeal therapies.

Disagree with this article?